Company news
Ningbo Menovo Pharmaceutical Co., Ltd. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
(603538)"Ningbo Menovo Pharmaceutical Co., Ltd."Report for Q3 2026
October 29, 2026
(603538)"Ningbo Menovo Pharmaceutical Co., Ltd."Announcement on Resolutions of the 33rd Meeting of the 5th Board of Directors
October 29, 2026
(603538)"Ningbo Menovo Pharmaceutical Co., Ltd."Announcement on Obtaining the European CEP Certificate for Pregabalin API
October 26, 2026
(603538)"Ningbo Menovo Pharmaceutical Co., Ltd."Announcement on Signing of Quadripartite Supervision Agreement Following the Change of Sponsor
October 21, 2026
(603538)"Ningbo Menovo Pharmaceutical Co., Ltd."Announcement on Obtaining Drug Registration Certificate for Tofacitinib Citrate Sustained-release Tablets by Wholly-owned Subsidiary
October 16, 2026
(603538)"Ningbo Menovo Pharmaceutical Co., Ltd."Announcement on Acceptance by Shanghai Stock Exchange of Application for 2026 Private Placement of A-Shares
October 16, 2026
Announcement on Change of Sponsor and Sponsor Representative
September 29, 2026
Announcement on Convening the 2026 Semi-annual Performance Briefing
September 23, 2026
Ningbo Menovo Pharmaceutical: Announcement on the Dilution of Immediate Returns, Measures to Mitigate Such Dilution and the Undertakings by Relevant Parties in Relation to the 2026 Private Placement of A-Shares (Revised Draft)
September 21, 2026
Announcement on Completion of the Industrial and Commercial Registration Change and Issuance of a New Business License
September 8, 2026
Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026
September 3, 2026
Notice on Convening the 2nd Extraordinary General Meeting in 2026
August 18, 2026
Announcement on Resolutions of the 30th Meeting of the 5th Board of Directors
August 11, 2026
Announcement on the Proposed Selection of the Wholly-owned Subsidiary in the 12th Batch of National Centralized Drug Procurement
August 5, 2026
Announcement on Change to "Drug Manufacturing License" of Controlled Subsidiary
July 13, 2026
Announcement on Progress in Outward Investment
July 3, 2026
Announcement on Abnormal Fluctuations in Stock Trading
July 2, 2026
Announcement on External Investment
July 1, 2026
Announcement on the Lifting and Listing of the 2nd Trade Restriction Period for Restricted Shares Granted under the Initial Granting of the 2024 Restricted Stock Incentive Plan
June 22, 2026
Announcement on No Provision of Financial Aid or Compensation for Investors Participating in Subscription Directly or through Stakeholders in This Issuance of A Shares to Specific Objects
June 4, 2026
Announcement on Convening Performance Briefing for 2025 and Q1 2026
June 1, 2026
Announcement on Completing Industrial and Commercial Change Registration and Obtaining New Business License
May 29, 2026
Announcement on the Lifting and Listing of the 1st Trade Restriction Period for Restricted Shares Granted under the Reserved Granting of the 2024 Restricted Stock Incentive Plan
May 28, 2026
Announcement on Abnormal Fluctuations in Stock Trading
May 26, 2026
Announcement on Resolutions of the 27th Meeting of the 5th Board of Directors
May 25, 2026
Announcement on Progress in Using Idle Raised Funds for Cash Management
May 20, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
May 18, 2026
Announcement on Redemption Results of “MENOVO Convertible Bonds" and Share Capital Changes
May 8, 2026
The Last Indicative Announcement on Implementation of Redemption and Delisting of "MENOVO Convertible Bonds"
May 6, 2026
the 8th Indicative Announcement on Implementation of Redemption and Delisting of "MENOVO Convertible Bonds"
April 30, 2026
the 7th Indicative Announcement on Implementation of Redemption and Delisting of "MENOVO Convertible Bonds"
April 29, 2026
the 6th Indicative Announcement on Implementation of Redemption and Delisting of "MENOVO Convertible Bonds"
April 28, 2026
Announcement on the Cumulative Number of Shares Converted from Convertible Bonds Reaching 10% of the Total Issued Shares Before Conversion and the Associated Share Changes
April 27, 2026
2025 Annual Report
April 24, 2026
The 3rd Indicative Announcement on Implementation of Redemption and Delisting of "MENOVO Convertible Bonds"
April 23, 2026
The 2nd Indicative Announcement on Implementation of Redemption and Delisting of "MENOVO Convertible Bonds"
April 22, 2026
the 1st Indicative Announcement on Implementation of Redemption and Delisting of "MENOVO Convertible Bonds"
April 21, 2026
Announcement on Implementation of Redemption and Delisting of "MENOVO Convertible Bonds"
April 20, 2026
Announcement on Redeeming "MENOVO Convertible Bonds" in Advance
April 13, 2026
Indicative Announcement on "MENOVO Convertible Bonds" Expected to Meet Conditions for Redemption
April 3, 2026
Announcement on Conversion Result of Convertible Bonds and Share Changes
April 1, 2026
Announcement on Abnormal Fluctuation of Convertible Bond Trading and Risk Warning in Stock Trading
March 27, 2026
Indicative Announcement on the Completion of Cancellation of Repurchased Shares and Passive Change in Equity of Shareholder with Over 5% Shares Reaching an Integral Multiple of 1%
February 24, 2026
Announcement on Selection of Products of the Wholly-owned Subsidiary for Continuation Procurement Under National Procurement Scheme After Agreement Expiry
February 12, 2026
Announcement on the Implementation of Repurchase and Cancellation of Equity Incentive Restricted Stocks
February 9, 2026
Announcement on Not Revising the Downward Conversion Price of "Menovo Convertible Bonds"
February 2, 2026
Announcement on Relocation of Company Office Premises
January 30, 2026
Announcement on the Holding Subsidiary Re-certified as High-tech Enterprise
January 29, 2026
Announcement on Expected Increase in Performance for 2025
January 26, 2026
Announcement on the Subsidiary Re-certified as High-tech Enterprise
January 22, 2026